Department of Nephrology, Weifang People's Hospital, Weifang, Shandong Province, China.
Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):662-670. doi: 10.26355/eurrev_201802_14291.
The aim of the present study was to examine the expression of miR-205 in renal cell carcinoma (RCC) tissue and carcinoma cells; also, we aimed to determine the association of miR-205 expression with the clinicopathological features and prognosis of RCC, and to explore the mechanism of miR-205.
Carcinoma tissue and adjacent normal tissue were collected from 60 patients with RCC, and the expression of miR-205 was determined by semi-quantitative PCR, followed by correlation analysis of miR-205 with clinicopathological features and prognosis. Subsequently, the human RCC line, ACHN, was transfected with miR-205, and the effect of miR-205 overexpression on the growth of RCC was examined by MTT assay. Moreover, the effect of miR-205 on the migration of colon cancer cells was studied by transwell assay. Additionally, immunohistochemistry and Western blot were used to investigate the epithelial-mesenchymal transition in renal cancer tissue.
The expression of miR-205 was downregulated in RCC tissue compared with adjacent non-cancerous tissue (p < 0.01). The expression of miR-205 was closely related to the infiltration and recurrence of tumors (p < 0.01), but was not correlated with a pathological grade or clinical stage (p > 0.05). We also found that overexpression of miR-205 in RCC significantly inhibited the growth of cancer cells (p < 0.01) and significantly reduced the migration ability (p < 0.01). The epithelial-mesenchymal transition occurs in RCC, and miR-205 might inhibit cell proliferation and migration by blocking the epithelial-mesenchymal transition.
The expression of miR-205 is low in RCC, and may play an important role throughout the progression of RCC. Further study of miR-205 may promote the development of a novel therapeutic approach for the treatment of RCC.
本研究旨在检测 miR-205 在肾细胞癌（RCC）组织和癌细胞中的表达，并探讨 miR-205 的表达与 RCC 临床病理特征和预后的相关性，同时研究 miR-205 的作用机制。
收集 60 例 RCC 患者的癌组织及癌旁正常组织，采用半定量 PCR 检测 miR-205 的表达情况，对 miR-205 与临床病理特征和预后的相关性进行分析。随后，将 miR-205 转染入人 RCC 细胞系 ACHN，通过 MTT 实验检测 miR-205 过表达对 RCC 生长的影响。通过 Transwell 实验研究 miR-205 对结肠癌细胞迁移的影响。采用免疫组化和 Western blot 检测肾癌细胞上皮间质转化。
与癌旁非癌组织相比，RCC 组织中 miR-205 的表达下调（p<0.01）。miR-205 的表达与肿瘤浸润和复发密切相关（p<0.01），但与病理分级或临床分期无关（p>0.05）。我们还发现，在 RCC 中过表达 miR-205 可显著抑制癌细胞的生长（p<0.01）和迁移能力（p<0.01）。RCC 中发生上皮间质转化，miR-205 可能通过阻断上皮间质转化抑制细胞增殖和迁移。
miR-205 在 RCC 中表达下调，可能在 RCC 的发生发展中发挥重要作用。对 miR-205 的进一步研究可能促进开发治疗 RCC 的新方法。
